Table 2.

Mendelian randomization (MR) estimates between accelerometer-based vigorous PA (fraction of accelerations>425 milli-gravities) and type 2 diabetes and glycemic traits

Method	No. of SNPs	OR/beta	95% CI	P value	Outcome
Inverse variance weighted (multiplicative random effects)	8	0.83	(0.56 to 1.232)	0.357	Type 2 diabetes
Weighted median	8	0.80	(0.58 to 1.11)	0.177	Type 2 diabetes
MR-PRESSO: outlier corrected	6	0.86	(0.60 to 1.21)	0.421	Type 2 diabetes
MRMix	8	1.45	(0.86 to 2.44)	0.165	Type 2 diabetes
Inverse variance weighted (multiplicative random effects)	6	−0.018	(−0.085 to 0.05)	0.606	HbA1c
Weighted median	6	0.016	(−0.07 to 0.102)	0.717	HbA1c
MR-PRESSO: raw	6	−0.018	(−0.079 to 0.043)	0.595	HbA1c
MRMix	6	−0.035	(−0.169 to 0.099)	0.609	HbA1C
Inverse variance weighted (multiplicative random effects)	6	0.065	(−0.11 to 0.24)	0.469	Fasting glucose
Weighted median	6	0.059	(−0.148 to 0.266)	0.578	Fasting glucose
MR-PRESSO: raw	6	0.065	(−0.11 to 0.24)	0.502	Fasting glucose
MRMix	6	−0.010	(−0.574 to 0.554)	0.972	Fasting glucose
Inverse variance weighted (multiplicative random effects)	6	0.069	(−0.071 to 0.209)	0.336	HOMA-B
Weighted median	6	0.013	(−0.17 to 0.197)	0.886	HOMA-B
MR-PRESSO: raw	6	0.069	(−0.071 to 0.209)	0.380	HOMA-B
MRMix	6	0.110	(−0.902 to 1.122)	0.831	HOMA-B
Inverse variance weighted (multiplicative random effects)	6	0.102	(−0.111 to 0.316)	0.349	HOMA-IR
Weighted median	6	−0.041	(−0.258 to 0.176)	0.708	HOMA-IR
MR-PRESSO: raw	6	0.102	(−0.111 to 0.316)	0.392	HOMA-IR
MRMix	6	−0.030	(−0.455 to 0.395)	0.890	HOMA-IR

HbA1c, hemoglobin A1c; HOMA-B, homeostasis model assessment of beta-cell function; HOMA-IR, homeostasis model assessment of insulin resistance; MR-PRESSO, MR-Pleiotropy RESidual Sum and Outlier; PA, physical activity; SNPs, single nucleotide polymorphisms.